Who
Jeffrey Chodakewitz
Director
Company insider
Files Form 4 as: Director, Schrodinger; Director, Adicet Bio; Director, Praxis Precision Medicines; Director, Tetraphase Pharmaceuticals; EVP Gmda, Cmo, Vertex Pharmaceuticals.
In numbers
- Trades disclosed
- 213
- Buys
- 0
- Sells
- 33
- Bought
- $0
- Sold
- $30.9M
- Companies
- 5
- Companies where not an officer
- 4
- First trade
- 13 Jun 2014
- Last trade
- 22 Jun 2026
- Last filed
- 23 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 22 Jun 2026filed 23 Jun 2026 | SDGR SchrodingerLife-science tools | SEC FORM 4 Code A | —8,141 at $0.00 | filing |
| 22 Jun 2026filed 23 Jun 2026 | SDGR Schrodingeroption or derivative · Life-science tools | SEC FORM 4 Code A | —13,313 at $0.00 | filing |
| 22 Jun 2026filed 23 Jun 2026 | SDGR Schrodingeroption or derivative · Life-science tools | SEC FORM 4 Code A | —13,313 at $0.00 | filing |
| 22 Jun 2026filed 23 Jun 2026 | SDGR SchrodingerLife-science tools | SEC FORM 4 Code A | —8,141 at $0.00 | filing |
| 21 Jun 2026filed 23 Jun 2026 | ACET Adicet Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —4,200 at $0.00 | filing |
| 21 Jun 2026filed 23 Jun 2026 | ACET Adicet Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —4,200 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PRAX Praxis Precision MedicinesBiotechnology | SEC FORM 4 Code A | —1,371 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PRAX Praxis Precision Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —648 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PRAX Praxis Precision Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —648 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PRAX Praxis Precision MedicinesBiotechnology | SEC FORM 4 Code A | —1,371 at $0.00 | filing |
| 26 Jun 2025filed 27 Jun 2025 | PRAX Praxis Precision Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,520 at $0.00 | filing |
| 18 Jun 2025filed 20 Jun 2025 | SDGR Schrodingeroption or derivative · Life-science tools | SEC FORM 4 Code A | —9,341 at $0.00 | filing |
| 18 Jun 2025filed 20 Jun 2025 | SDGR SchrodingerLife-science tools | SEC FORM 4 Code A | —5,997 at $0.00 | filing |
| 11 Jun 2025filed 13 Jun 2025 | ACET Adicet Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —26,400 at $0.00 | filing |
| 11 Jun 2025filed 13 Jun 2025 | ACET Adicet BioBiotechnology | SEC FORM 4 Code A | —5,900 at $0.00 | filing |
| 21 Aug 2024filed 23 Aug 2024 | ACET Adicet Biooption or derivative · Biotechnology | SEC FORM 4 Code D | —30,000 at $0.00 | filing |
| 21 Aug 2024filed 23 Aug 2024 | ACET Adicet Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 21 Aug 2024filed 23 Aug 2024 | ACET Adicet Biooption or derivative · Biotechnology | SEC FORM 4 Code D | —18,500 at $0.00 | filing |
| 21 Aug 2024filed 23 Aug 2024 | ACET Adicet Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —18,500 at $0.00 | filing |
| 21 Aug 2024filed 23 Aug 2024 | ACET Adicet Biooption or derivative · Biotechnology | SEC FORM 4 Code D | —18,500 at $0.00 | filing |
News
Head to Head Analysis: Caribou Biosciences (NASDAQ:CRBU) & Vertex Pharmaceuticals (NASDAQ:VRTX)VRTX · tickerreport.com · 14 Oct 2026Vertex Pharmaceuticals Incorporated: Vertex to Present New Data on ALYFTREK at the North American Cystic Fibrosis ConferenceVRTX · finanznachrichten.de · 9 Oct 2026
0 headlines in the last 90 days name Jeffrey Chodakewitz; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.